➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Mallinckrodt
AstraZeneca
Medtronic
Merck

Last Updated: October 31, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OMONTYS

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Omontys

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00097747 Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers Completed Affymax Phase 1 2004-08-01 The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.
NCT00109291 Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease Terminated Affymax Phase 2 2005-03-01 To evaluate the safety profile of single intravenous (IV) dose levels of peginesatide in participants with chronic kidney disease(CKD) not on dialysis.
NCT00228436 Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients Completed Affymax Phase 2 2005-09-01 The purpose of this study was to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneous injections of peginesatide in participants with chronic kidney disease (CKD) not on dialysis who had not received erythropoiesis stimulating agent (ESA) treatment.
NCT00228449 Peginesatide for Anemia in Chronic Hemodialysis Patients Completed Affymax Phase 2 2005-07-01 The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of peginesatide in participants with chronic kidney disease (CKD) who are on hemodialysis.
NCT00272662 Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy Completed Affymax Phase 2 2006-01-01 The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneously administered injections of peginesatide in anemic cancer participants receiving chemotherapy.
NCT00314795 Efficacy and Safety of Peginesatide in the Treatment of Anemia in Patients With Chronic Kidney Disease Completed Takeda Phase 2 2006-04-01 The purpose of this study is to evaluate the ability of peginesatide to increase and maintain increased hemoglobin levels in participants with chronic kidney disease (CKD) (either not on dialysis, receiving regular hemodialysis or peritoneal dialysis, or following renal transplant) with confirmed antibody-mediated pure red cell aplasia (PRCA).
NCT00372489 Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD Terminated Affymax Phase 2 2006-09-01 The purpose of this study was to evaluate the long term safety and tolerability of peginesatide for the maintenance of hemoglobin in participants with chronic kidney disease (CKD) who had received at least 24 weeks of peginesatide treatment in an earlier study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Omontys

Condition Name

Condition Name for Omontys
Intervention Trials
Anemia 17
Chronic Kidney Disease 14
Chronic Renal Failure 13
Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Omontys
Intervention Trials
Kidney Failure, Chronic 14
Kidney Diseases 14
Anemia 14
Renal Insufficiency, Chronic 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Omontys

Trials by Country

Trials by Country for Omontys
Location Trials
United States 160
United Kingdom 10
Poland 5
Romania 4
Bulgaria 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Omontys
Location Trials
California 10
Texas 10
New York 8
Florida 8
Michigan 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Omontys

Clinical Trial Phase

Clinical Trial Phase for Omontys
Clinical Trial Phase Trials
Phase 4 1
Phase 3 5
Phase 2 11
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Omontys
Clinical Trial Phase Trials
Completed 14
Terminated 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Omontys

Sponsor Name

Sponsor Name for Omontys
Sponsor Trials
Affymax 16
Takeda 9
Amgen 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Omontys
Sponsor Trials
Industry 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Moodys
Johnson and Johnson
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.